Pathogenomix
Pathogenomix is a company dedicated to rapid and accurate pathogen identification using DNA sequencing technologies. Their solutions, including Ripseq and Patho-Seq, are designed to provide fast, reliable, and comprehensive microbial diagnostics without the need for extensive bioinformatics resources. They focus on delivering results in less than five minutes, supporting both Sanger and Next Generation Sequencing (NGS), and offer curated databases for precise identification. Their mission is to improve infectious disease diagnosis and treatment through innovative sequencing-based tools.
Industries
Nr. of Employees
small (1-50)
Pathogenomix
Pathogenomix, Inc., Santa Cruz, CA
Patents
Systems and methods for removing human genetic data from genetic sequences
US-11914653-B1
View Details
Systems and methods for removing human genetic data from genetic sequences
US-11914653-B1
View DetailsProducts
Targeted sequencing analysis platform (SaaS)
A cloud-based platform that preprocesses targeted NGS files locally to reduce upload size, analyzes reads against curated reference databases, and returns identification reports for clinical samples.
Curated amplicon reference databases
Maintained and filtered reference sequence collections for common diagnostic targets (examples: 16S rRNA, ITS, rpoB) with tools for user curation and taxonomy cross-referencing.
Protocols and method documentation
Downloadable laboratory protocols and product sheets describing primer protocols, group-specific primers, and implementation notes for targeted sequencing workflows.
Targeted sequencing analysis platform (SaaS)
A cloud-based platform that preprocesses targeted NGS files locally to reduce upload size, analyzes reads against curated reference databases, and returns identification reports for clinical samples.
Curated amplicon reference databases
Maintained and filtered reference sequence collections for common diagnostic targets (examples: 16S rRNA, ITS, rpoB) with tools for user curation and taxonomy cross-referencing.
Protocols and method documentation
Downloadable laboratory protocols and product sheets describing primer protocols, group-specific primers, and implementation notes for targeted sequencing workflows.
Services
Web-accessible analytics service that accepts Sanger and targeted NGS sequence files, performs automated preprocessing and identification against curated reference databases, and produces clinician-ready reports.
Maintained amplicon reference databases with automated filtering, taxonomy cross-referencing and user-facing curation tools to annotate, accept or reject references for medically relevant identification.
Published protocols and primer design guidance for targeted marker amplification (including universal and group-specific primer protocols) to support implementation of sequencing-based pathogen ID workflows.
Web-accessible analytics service that accepts Sanger and targeted NGS sequence files, performs automated preprocessing and identification against curated reference databases, and produces clinician-ready reports.
Maintained amplicon reference databases with automated filtering, taxonomy cross-referencing and user-facing curation tools to annotate, accept or reject references for medically relevant identification.
Published protocols and primer design guidance for targeted marker amplification (including universal and group-specific primer protocols) to support implementation of sequencing-based pathogen ID workflows.
Expertise Areas
- Targeted amplicon sequencing for pathogen identification
- Polymicrobial sample analysis and mixed-signal deconvolution
- Curated microbial reference database development and curation
- Cloud-based bioinformatics SaaS for clinical diagnostics
Key Technologies
- Sanger sequencing analysis
- Targeted next-generation sequencing (amplicon sequencing)
- Local NGS pre-processing and data reduction
- Cloud-based sequence analysis and reporting
News & Updates
Pathogenomix granted FDA Breakthrough Device Designation
The FDA has granted Pathogenomix a Breakthrough Device Designation for its Patho-Seq assay, which can rapidly detect and identify hundreds of bacteria from clinical samples, significantly advancing infectious disease diagnosis.
Pathogenomix granted FDA Breakthrough Device Designation
The Patho-Seq test has the potential to significantly improve infectious disease treatment by rapidly identifying bacteria in life-threatening infections, including sepsis and bacterial meningitis.
Rapid & accurate pathogen ID
Pathogenomix offers a rapid, easy-to-use solution for pathogen identification that reduces analysis time by up to 90% and works with any sequencing technology.
FDA Breakthrough Device Designation for Patho-Seq
Pathogenomix's Patho-Seq has received FDA Breakthrough Device Designation, highlighting its potential to transform infectious disease diagnostics.
Platform agnostic pathogen analysis
Ripseq can analyze both NGS and Sanger sequencing files directly from specimens, providing results in less than five minutes.
Curated databases for accurate ID
Ripseq databases are automatically curated, up-to-date, and designed to ensure reliable pathogen identification.
Pathogenomix granted FDA Breakthrough Device Designation
The FDA has granted Pathogenomix a Breakthrough Device Designation for its Patho-Seq assay, which can rapidly detect and identify hundreds of bacteria from clinical samples, significantly advancing infectious disease diagnosis.
Pathogenomix granted FDA Breakthrough Device Designation
The Patho-Seq test has the potential to significantly improve infectious disease treatment by rapidly identifying bacteria in life-threatening infections, including sepsis and bacterial meningitis.
Rapid & accurate pathogen ID
Pathogenomix offers a rapid, easy-to-use solution for pathogen identification that reduces analysis time by up to 90% and works with any sequencing technology.
FDA Breakthrough Device Designation for Patho-Seq
Pathogenomix's Patho-Seq has received FDA Breakthrough Device Designation, highlighting its potential to transform infectious disease diagnostics.
Platform agnostic pathogen analysis
Ripseq can analyze both NGS and Sanger sequencing files directly from specimens, providing results in less than five minutes.
Curated databases for accurate ID
Ripseq databases are automatically curated, up-to-date, and designed to ensure reliable pathogen identification.